Hangzhou Sciwind Biosciences Co Ltd, a clinical-stage biotech company focusing on research and development of innovative biologics, announced on Sunday that it has received approval for the clinical trial of company's XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH) from China's regulator, NMPA.
Two additional clinical trial applications with the product were earlier approved for the treatment of type 2 diabetes mellitus and overweight/obesity in 2020.
The company is to start a series of phase two trials including multiple metabolic indications, including diabetes, obesity and NASH etc.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults